Navigation Links
NeurogesX to Present at Upcoming Fall Conferences
Date:9/2/2009

SAN MATEO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at two upcoming conferences in New York City: the Rodman & Renshaw 11th Annual Healthcare Conference, to be held September 9 - 11th, 2009, and the BioCentury NewsMakers in the Biotech Industry Conference, to be held September 16, 2009.

Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will also be available to respond to questions immediately following the presentation and to participate in one-on-one meetings with investors attending the conference.

    Event:  Rodman & Renshaw 11th Annual Healthcare Conference
    Date:   Thursday, September 10, 2009
    Time:   11:15 a.m. ET
    Place:  New York Palace Hotel, New York, NY (Henry Salon, 5th
            Floor)

    Event:  BioCentury NewsMakers in the Biotech Industry
            Conference
    Date:   Wednesday, September 16, 2009
    Time:   10:00 a.m. ET
    Place:  Millennium Broadway Hotel & Conference Center,
            New York, NY (Room 502)

Both presentations will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at www.neurogesx.com. The webcasts will be archived for 90 days.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently planning the design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and development activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.               The Ruth Group
    Stephen Ghiglieri             Sara Pellegrino (investors)
    Chief Financial Officer       (646) 536-7002
    (650) 358-3310                spellegrino@theruthgroup.com

                                  Jason Rando (media)
                                  (646) 536-7025
                                  jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX Appoints New Board Director and Audit Committee Chairman
2. NeurogesX Reports Second Quarter 2009 Results
3. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
4. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
5. NeurogesX Added to Russell 3000 Index
6. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
7. NeurogesX to Present at Needham Life Sciences Conference
8. NeurogesX Receives European Commission Approval for Qutenza(TM)
9. NeurogesX Reports First Quarter 2009 Results
10. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
11. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... MANASSAS, Va. , Feb. 5, 2016 ... organization, is poised to assist the medical and life ... concerns around Zika Virus infection.   CDC ... --> Zika virus is a single-stranded ... also includes the West Nile, Dengue and Chikungunya Viruses. ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... -- - New FDA action date of July ... date of July 22, 2016   --> ... 2016   - Lifitegrast has the potential ... the treatment of signs and symptoms of dry eye disease in ... be the only product approved in the U.S. in the past decade indicated for the ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Forensics Club, takes place February 5-6 at the University’s student center, Kehr ... activities such as workshops and competitions for ample networking, learning and collaborating ...
Breaking Biology Technology:
(Date:1/15/2016)... 15, 2016 Recent publicized breaches in cyber ... new ways to ensure data security and user authentication ... and Android that ties a user,s mobile ... into a hardware authorization token. Customer service agents who ... on their KodeKey enabled device to verify their identity. ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the ... nearly 10,000 retail locations, web and mobile, today ... $40 million from existing investors. ... be devoted to further innovate higi,s health platform ... and web portal – including expanding services and ...
(Date:1/7/2016)... LONDON , Jan. 7, 2016 ... demand for biopharmaceutical products such as biologics and ... pressure to reduce healthcare expenditure, growing demand for ... growing aging population. Biosimilars are similar versions of ... with regards to their quality, safety, and efficacy. ...
Breaking Biology News(10 mins):